Emphasis on infusion therapy with a polyionic succinate-methionine complex in the treatment of non-alcoholic fatty liver disease

Background. After assessment of the main effects of the active components of Remaxol, it was suggested that it plays unique role in the treatment of non-alcoholic fatty liver disease (NAFLD), especially at the stage of steatohepatitis. Description of the clinical case. The article discusses the key aspects of the case history of patient A., born in 1993, with the main diagnosis of non-alcoholic steatohepatitis, grade 1 biochemical activity, fibrosis F2-3 according to METAVIR; according to the transient elastography data (04/29/2020) - F3 according to METAVIR, Histological Activity Index (Knodell Score) - 1; A0 according to METAVIR (liver biopsy data from 06/08/2020). The clinical effect of Remaxol in the treatment of this patient was manifested in the relief of astheno-vegetative syndrome, and according to the laboratory tests - by a decrease in the severity of the biochemical manifestations of cytolytic and cholestatic syndromes, and normalization of blood lipids. Conclusion. Thus, it was concluded that Remaxol is a unique drug successfully used in the treatment of dysmetabolic disorders, which is indispensable in the complex therapy of NAFLD, especially at the stage of steatohepatitis.

steatohepatitis, Remaxol, polyionic succinate-methionine complex, non-alcoholic fatty liver disease, fatty liver disease